{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:12:18Z","timestamp":1784988738115,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,6,15]]},"DOI":"10.1007\/s10637-019-00769-5","type":"journal-article","created":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T05:04:21Z","timestamp":1556255061000},"page":"548-558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8597-8459","authenticated-orcid":false,"given":"M. Christina","family":"Cox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Pelliccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Marcheselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Battistini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Arcari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Anticoli","family":"Borza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Casaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"di Landro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Caridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Tafuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Bocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Musuraca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,26]]},"reference":[{"issue":"4","key":"769_CR1","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3109\/10428194.2014.953142","volume":"56","author":"A Tucci","year":"2015","unstructured":"Tucci A, Martelli M, Rigacci L, Riccomagno P, Cabras MG, Salvi F et al (2015) Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymphoma 56(4):921\u2013926","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"769_CR2","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1182\/bloodadvances.2017011031","volume":"1","author":"AG Dinmohamed","year":"2017","unstructured":"Dinmohamed AG, Issa DE, Van der Poel MWM, Schouten HC, Lugtenburg PJ, Chamuleau MED et al (2017) Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015. Blood Advances 1(21):1839\u20131841","journal-title":"Blood Advances"},{"issue":"3","key":"769_CR3","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/annonc\/mdx413","volume":"29","author":"C Buske","year":"2018","unstructured":"Buske C, Hutchings M, Ladetto M, Goede V, Mey U, Soubeyran P (2018) ESMO Lymphoma Consensus Conference Panel Members. ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Ann Oncol 29(3):544\u2013562","journal-title":"Ann Oncol"},{"issue":"5","key":"769_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S et al (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12(5):460\u2013468","journal-title":"Lancet Oncol"},{"key":"769_CR5","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","volume":"4","author":"F Peyrade","year":"2017","unstructured":"Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Ferm\u00e9 C et al (2017) Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematology 4:e46\u2013e55","journal-title":"Lancet Haematology"},{"issue":"1","key":"769_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3109\/10428194.2013.788176","volume":"55","author":"F Merli","year":"2014","unstructured":"Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Ferrari A et al (2014) Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. Leuk Lymphoma 55(1):38\u201343","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"769_CR7","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1182\/blood-2017-05-736975","volume":"130","author":"RJ Lin","year":"2017","unstructured":"Lin RJ, Behera M, Diefenbach CS (2017) Flowers CR Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. Blood. 130(20):2180\u20132185","journal-title":"Blood."},{"issue":"8","key":"769_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3324\/haematol.2017.186569","volume":"103","author":"S Storti","year":"2018","unstructured":"Storti S, Spina M, Pesce EA, Salvi F, Merli M, Ruffini A et al (2018) Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi. Haematologica. 103(8):1345\u20131350","journal-title":"Haematologica."},{"issue":"4","key":"769_CR9","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","volume":"32","author":"PA Fields","year":"2014","unstructured":"Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P et al (2014) De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. J Clin Oncol 32(4):282\u2013287","journal-title":"J Clin Oncol"},{"issue":"1","key":"769_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/hon.2425","volume":"36","author":"S Luminari","year":"2018","unstructured":"Luminari S, Viel E, Ferreri AJM, Zaja F, Chimienti E, Musuraca G et al (2018) Non pegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. Hematol Oncol 36(1):68\u201375","journal-title":"Hematol Oncol"},{"key":"769_CR11","doi-asserted-by":"publisher","unstructured":"Maybury B, Kimpton G, Otton S (2018) A retrospective multicentre study of COCKLE, an oral chemotherapy regimen, as palliative treatment for high grade lymphoma. British J Haematology. https:\/\/doi.org\/10.1111\/bjh.15637","DOI":"10.1111\/bjh.15637"},{"issue":"5","key":"769_CR12","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3109\/10428194.2015.1096356","volume":"57","author":"A Rashidi","year":"2016","unstructured":"Rashidi A, Oak E, Carson KR, Wagner-Johnston ND, Kreisel F, Bartlett NL (2016) Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria. Leuk Lymphoma 57(5):1191\u20131193","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"769_CR13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1634\/theoncologist.2011-0417","volume":"17","author":"M Spina","year":"2012","unstructured":"Spina M, Balzarotti M, Uziel L, Ferreri AJ, Fratino L, Magagnoli M et al (2012) Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist 17(6):838\u2013846","journal-title":"Oncologist"},{"key":"769_CR14","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1016\/S2352-3026(18)30054-1","volume":"5","author":"QD Shen","year":"2018","unstructured":"Shen QD, Zhu HY, Wang L, Fan L, Liang JH, Cao L et al (2018) Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial. Lancet Haematology 5:e261\u2013e269","journal-title":"Lancet Haematology"},{"issue":"3","key":"769_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjh.13619","volume":"173","author":"TA Eyre","year":"2016","unstructured":"Eyre TA, Salisbury R, Eyre DW, Watson C, Collins GP, Hatton CS et al (2016) Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma. Br J Haematol 173(3):487\u2013491","journal-title":"Br J Haematol"},{"issue":"10","key":"769_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11864-018-0565-6","volume":"19","author":"A Kumar","year":"2018","unstructured":"Kumar A, Fraz MA, Usman M, Malik SU, Ijaz A, Durer C, Durer S, Tariq MJ, Khan AY, Qureshi A, Faridi W, Nasar A, Anwer F (2018 Sep 1) Treating Diffuse Large B Cell Lymphomain the Very Old or Frail Patients. Curr Treat Options in Oncol 19(10):50","journal-title":"Curr Treat Options in Oncol"},{"issue":"17","key":"769_CR17","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","volume":"31","author":"K Ohmachi","year":"2013","unstructured":"Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N et al (2013) Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 31(17):2103\u20132109","journal-title":"J Clin Oncol"},{"issue":"8","key":"769_CR18","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3109\/10428194.2015.1106536","volume":"57","author":"A Arcari","year":"2016","unstructured":"Arcari A, Chiappella A, Spina M, Zanlari L, Bernuzzi P, Valenti V et al (2016) Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. Leuk Lymphoma 57(8):1823\u20131830","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"769_CR19","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00280-009-0941-9","volume":"64","author":"G Corazzelli","year":"2009","unstructured":"Corazzelli G, Capobianco G, Arcamone M, Ballerini PF, Iannitto E, Russo F et al (2009) Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory\/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 64(5):907\u2013916","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"769_CR20","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1023\/A:1012501305214","volume":"12","author":"D Machover","year":"2001","unstructured":"Machover D, Delmas-Marsalet B, Misra SC, Gumus Y, Goldschmidt E (2001 Oct) Schilf A, et al Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. Ann Oncol 12(10):1439\u20131443","journal-title":"Ann Oncol"},{"issue":"11","key":"769_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","volume":"13","author":"G Bocci","year":"2016","unstructured":"Bocci G, Kerbel R (2016) Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol 13(11):659\u2013673","journal-title":"Nat Rev Clin Oncol"},{"key":"769_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.canlet.2018.06.002","volume":"432","author":"G Natale","year":"2018","unstructured":"Natale G, Bocci G (2018) Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data. Cancer Lett 432:28\u201337","journal-title":"Cancer Lett"},{"issue":"12","key":"769_CR23","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1002\/cncr.23422","volume":"112","author":"M Coleman","year":"2008","unstructured":"Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R et al (2008) Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring\/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 112(12):2228\u20132232","journal-title":"Cancer."},{"issue":"4","key":"769_CR24","doi-asserted-by":"publisher","first-page":"01","DOI":"10.1007\/s00280-016-3136-1","volume":"78","author":"J Zeng","year":"2016","unstructured":"Zeng J, Yang L, Huang F, Hong T, He Z, Lei J et al (2016) The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 78(4):01\u201308","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"769_CR25","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1186\/s12885-018-4885-5","volume":"18","author":"RC Schelker","year":"2018","unstructured":"Schelker RC, Herr W, Reichle A, Vogelhuber M (2018) Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience. BMC Cancer 18(1):1000","journal-title":"BMC Cancer"},{"issue":"1","key":"769_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00432-018-2772-8","volume":"145","author":"HM Witte","year":"2019","unstructured":"Witte HM, Riecke A, Mayer T, Bartscht T, Rades D (2019 Jan) Lehnert H et alTrofosfamide in the treatment of elderly or frailpatients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 145(1):129\u2013136","journal-title":"J Cancer Res Clin Oncol"},{"key":"769_CR27","doi-asserted-by":"crossref","unstructured":"Thompson DS, Hainsworth JD, Hande KR, Holzmer MC, Greco FA (1993) Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I\/II study. J Clin Oncol","DOI":"10.1200\/JCO.1993.11.7.1322"},{"issue":"9","key":"769_CR28","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/oxfordjournals.annonc.a010802","volume":"7","author":"M Balzarotti","year":"1996","unstructured":"Balzarotti M, Santoro A, Tondini C, Fornier M, Bonadonna G (1996 Nov) Activity of singleagent vinorelbine in pretreated non-Hodgkin's lymphoma. Ann Oncol 7(9):970\u2013972","journal-title":"Ann Oncol"},{"issue":"3","key":"769_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/(SICI)1099-1069(199809)16:3<101::AID-HON629>3.0.CO;2-#","volume":"16","author":"S Rule","year":"1998","unstructured":"Rule S, Tighe M, Davies S, Johnson S (1998 Sep) Vinorelbine in the treatment of lymphoma. Hematol Oncol 16(3):101\u2013105","journal-title":"Hematol Oncol"},{"issue":"10","key":"769_CR30","first-page":"2731","volume":"62","author":"S Man","year":"2002","unstructured":"Man S, Bocci G, Francia G, Green SK, Jothy S (2002 May 15) Hanahan D et al Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62(10):2731\u20132735","journal-title":"Cancer Res"},{"issue":"15","key":"769_CR31","first-page":"4342","volume":"63","author":"F Bertolini","year":"2003","unstructured":"Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS (2003 Aug 1) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effectson the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63(15):4342\u20134346","journal-title":"Cancer Res"},{"issue":"10","key":"769_CR32","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1093\/annonc\/mdh384","volume":"15","author":"VR Rozados","year":"2004","unstructured":"Rozados VR, S\u00e1nchez AM, Gervasoni SI, Berra HH, Matar P, Graciela SO (2004 Oct) Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcomaregression, and is devoid of toxicity. Ann Oncol 15(10):1543\u20131550","journal-title":"Ann Oncol"},{"key":"769_CR33","doi-asserted-by":"crossref","unstructured":"Briasoulis E, Aravantinos G, Kouvatseas G, Pappas P, Biziota E, Sainis, I, et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study BMC Cancer 2013;13:263.","DOI":"10.1186\/1471-2407-13-263"},{"issue":"15","key":"769_CR34","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1016\/j.ejca.2012.04.012","volume":"48","author":"V Minard-Colin","year":"2012","unstructured":"Minard-Colin V, Ichante JL, Nguyen L, Paci A, Orbach D, Bergeron C et al (2012 Oct) Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma--a report from the Soci\u00e9t\u00e9 Fran\u00e7aise des Cancers et leuc\u00e9mies del'Enfant et de l'adolescent (SFCE). Eur J Cancer 48(15):2409\u20132416","journal-title":"Eur J Cancer"},{"key":"769_CR35","doi-asserted-by":"crossref","unstructured":"Mavroeidis L, Sheldon H, Briasoulis E, Marselos M, Pappas P, Harris AL (2015) Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition. Int J Oncol","DOI":"10.3892\/ijo.2015.3059"},{"key":"769_CR36","unstructured":"Launay S, Sabatier R, Brunelle S, Esterni B, Tarpin C, Viret Fet al . METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors. Anticancer Res 2016 Jan;36(1):293-299."},{"issue":"10","key":"769_CR37","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/s41416-018-0076-z","volume":"118","author":"S Orecchioni","year":"2018","unstructured":"Orecchioni S, Talarico G, Labanca V, Calleri A, Mancuso P, Bertolini F (2018 May) Vinorelbine, cyclophosphamide and 5-FU effects on the circulating andi ntratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. Br J Cancer 118(10):1329\u20131336. https:\/\/doi.org\/10.1038\/s41416-018-0076-z","journal-title":"Br J Cancer"},{"key":"769_CR38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.bcp.2018.04.011","volume":"152","author":"P Orlandi","year":"2018","unstructured":"Orlandi P, Di Desidero T, Salvia G, Muscatello B, Francia G, Bocci G (2018) Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R\/T790M cells to reversible EGFR tyrosine kinase inhibitors. Biochem Pharmacol 152:327\u2013337","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"769_CR39","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/bjh.15039","volume":"183","author":"MC Cox","year":"2018","unstructured":"Cox MC, Musuraca G, Battistini R, Casaroli I, Zoli V, Anticoli-Borza P et al (2018) Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit. Br J Haematol 183(5):819\u2013822","journal-title":"Br J Haematol"},{"issue":"20","key":"769_CR40","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 127(20):2375\u20132390","journal-title":"Blood."},{"key":"769_CR41","doi-asserted-by":"crossref","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. Blood. 2018 Feb 1;131(5):587-588","DOI":"10.1182\/blood-2017-11-817775"},{"issue":"5","key":"769_CR42","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"key":"769_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093903","volume":"9","author":"MC Cox","year":"2014","unstructured":"Cox MC, Di Napoli A, Scarpino S, Salerno G, Tatarelli C, Talerico C et al (2014) Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component. PLoS One 9:e93903","journal-title":"PLoS One"},{"key":"769_CR44","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.3324\/haematol.2016.147256","volume":"101","author":"PL Zinzani","year":"2016","unstructured":"Zinzani PL, Pellegrini C, Argnani L, Broccoli A (2016) Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab. Haematologica. 101:e385\u2013e386. https:\/\/doi.org\/10.3324\/haematol.2016.147256","journal-title":"Haematologica."},{"key":"769_CR45","doi-asserted-by":"publisher","unstructured":"Houot R, Cartron G, Bijou F, de Guibert S, Salles GA., Fruchart C, et al. Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse\/refractory aggressive lymphoma: a phase II LYSA study. Leukemia. 2018; https:\/\/doi.org\/10.1038\/s41375-018-0282-y.","DOI":"10.1038\/s41375-018-0282-y"},{"issue":"6","key":"769_CR46","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s10637-016-0385-0","volume":"34","author":"T Di Desidero","year":"2016","unstructured":"Di Desidero T, Derosa L, Galli L, Orlandi P, Fontana A, Fioravanti A et al (2016) Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. Investig New Drugs 34(6):760\u2013770","journal-title":"Investig New Drugs"},{"key":"769_CR47","doi-asserted-by":"crossref","unstructured":"NL Berinstein, AJ Grillo-L\u00f3pez, CA White, et al: Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma Ann Oncol 9: 995\u2013 1001,1998","DOI":"10.1023\/A:1008416911099"},{"issue":"14","key":"769_CR48","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","volume":"129","author":"D Rossi","year":"2017","unstructured":"Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, Rasi S et al (2017) Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 129(14):1947\u20131957","journal-title":"Blood."},{"key":"769_CR49","unstructured":"Park SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL et al. A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse 10.1111\/bjh.14232. Epub 2016 Jul 22. PubMed PMID: 27448091; PubMed Central PMCID:"},{"issue":"17","key":"769_CR50","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.1158\/0008-5472.CAN-16-3130","volume":"77","author":"J Ciccolini","year":"2017","unstructured":"Ciccolini J, Barbolosi D, Meille C, Lombard A, Serdjebi C, Giacometti S et al (2017) Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy. Cancer Res 77(17):4723\u20134733","journal-title":"Cancer Res"},{"key":"769_CR51","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.canlet.2017.02.005","volume":"400","author":"RS Kerbel","year":"2017","unstructured":"Kerbel RS (2017) Shaked Y The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease. Cancer Lett 400:293\u2013304","journal-title":"Cancer Lett"},{"issue":"44","key":"769_CR52","doi-asserted-by":"publisher","first-page":"27448","DOI":"10.18632\/oncotarget.25422","volume":"9","author":"MG Cerrito","year":"2018","unstructured":"Cerrito MG, De Giorgi M, Pelizzoni D, Bonomo SM, Digiacomo N, Scagliotti A et al (2018) Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. Oncotarget. 9(44):27448\u201327459","journal-title":"Oncotarget."},{"issue":"5","key":"769_CR53","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.trecan.2017.03.011","volume":"3","author":"N Andr\u00e9","year":"2017","unstructured":"Andr\u00e9 N, Tsai K, Carr\u00e9 M, Pasquier E (2017 May) Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all? Trends Cancer 3(5):319\u2013325","journal-title":"Trends Cancer"},{"issue":"17","key":"769_CR54","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1158\/1078-0432.CCR-06-0474","volume":"12","author":"R Buckstein","year":"2006","unstructured":"Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R et al (2006) High-Dose celecoxib and metronomic \"low-dose\" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 12(17):5190\u20135198","journal-title":"Clin Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00769-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00769-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00769-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:32:30Z","timestamp":1678559550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00769-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6,15]]}},"alternative-id":["769"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00769-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,26]]},"assertion":[{"value":"24 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author M Christina Cox declares that she has no conflict of interest;Author Sabrina Pelliccia<sup>,<\/sup> declares that she has no conflict of interest,Author Luigi Marcheselli<sup>,<\/sup> declares that he has no conflict of interest;Author Roberta Battistini, declares that she has no conflict of interest;Author Annalisa Arcari, declares that she has no conflict of interest;Author Paola Anticoli Borza, declares that she has no conflict of interest;Author Caterina Patti , declares that she has no conflict of interest;Author Ivana Casaroli , declares that she has no conflict of interest;Author Francesca di Landro , declares that she has no conflict of interest;Author Arianna Di Napoli<sup>,<\/sup> declares that she has no conflict of interest;Author Francesca Fabbri, declares that she has no conflict of interest;Author Matteo Caridi, declares that he has no conflict of interest;Author Agostino Tafuri , declares that he has no conflict of interest;Author Guido Bocci , declares that he has no conflict of interest;Author Gerardo Musuraca<sup>,,<\/sup> declares that he has no conflict of interest;","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Sapienza ethics committee (EC approval n\u00b0 4640).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}